Summary
49 / 100 · Bulios Score
What speaks for it
- You pay 6.0 USD for 1 USD of yearly profit, little for its sector.
- Earnings per share grew by 10% a year over the last 3 years.
What to watch
- It cut its dividend by 75% last year.
- It missed profit estimates 6 times in the last 8 quarters.
- Out of every 100 USD of revenue, only 4.7 USD is left as net profit.
- Revenue grew by only 1.3% a year over the last 3 years.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks cheapToday you pay 6.0 USD for 1 USD of yearly profit.
Valuation in detailIs it growing?
SlowlyRevenue (USD)
Diluted EPS (USD)
- Analyst estimate
Revenue grew by 0.6% a year over 5 years. Over the last 3 years it grew by 1.3% a year. Earnings per share grew by 10% a year over the last 3 years.
Growth in detailDoes it make money?
PoorlyWhere 100 USD of revenue goes
- Cost of sales 54 USD
- Sales and administration 42 USD
- Taxes and other -1.2 USD
- Net profit 4.7 USD
Net profit, industry median (Insurance - Specialty) 14 USD
Out of every 100 USD of revenue, 4.7 USD is left as net profit.
Profitability in detailIs it financially healthy?
Banks and insurers work with their customers' money, so their debt is judged differently; see the health section for their capital figures.
Financial health in detailDoes it pay a dividend?
Small, safe- Yield
- 1.00%
- Paid out of profit
- 6.0%
You receive $0.04 per share a year. The company covers the payout with ease.
Dividends in detailWhat do analysts expect?
Neutral- Buy 5
- Hold 7
- Sell 2
Today's price within the analysts' price targets
The average target of $4 is 0.8% above today's price. 36% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
Fiscal year 2025By product
- Excess And Surplus Lines 91%
- Specialty Admitted Insurance 8.8%
By region
The company reports no revenue by region.
Excess And Surplus Lines brings in 91% of revenue.
Segments in detail